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Several developments have been proposed to improve cancer
chemotherapy. They include: increased drug dosage (Powis,
1985); altered schedules of administration, such as prolonged
infusions or multiple injections (Desoize & Garrett, 1989;
Lokich et al., 1989; Clark & Slevin, 1987); and pharmaco-
kinetic monitoring. Clinical pharmacokinetics enables the in-
dividual distribution and metabolism of drugs to be studied
and the correlation of pharmacokinetic measurements with
the drug's efficacy and toxicity. Here we report an analysis of
the pharmacokinetics of Etoposide (VP 16) in 32 courses of
treatment in 14 patients with solid tumours.
Fourteen patients were the subjects of the pharmacokinetic
studies, 10 had non-small cell lung cancer, one a non-
Hodgkin's lymphoma, one a breast cancer and in two
patients the site of primary cancer was unknown. Seven
patients responded to chemotherapy and seven did not re-
spond. The pharmacokinetics were studied on 32 occasions.
Creatinine clearance was measured during the first 24 h of
infusion in the last 10 of these studies. Pharmacokinetics
were studied on one to three occasions per patient (Table I).
Etoposide was infused for 5 days (50 mg m2 day-' x 5),
one course was given every 4 weeks. Two volumetric pumps
were used for each continuous infusion. Etoposide was given
with cisplatin (CDDP, 20 mg m-2 day-' x 5), except in one
patient treated with cyclophosphamide (CPM, 500 mg at JO).
Toxicity (myelosuppression) and drug efficacy were eval-
uated after one and three courses respectively, according to
WHO criteria (Miller et al., 1981). The responders showed a
partial or complete response. A blood cell count was made
weekly after starting the treatment.
Blood was drawn into heparinised tubes each morning at
08:30 h during the course of treatment. The etoposide assay
used the high performance liquid chromatographic method of
Cunningham et al. (1986) with minor modifications. Briefly,
etoposide was extracted using dichloromethane, evaporated
to dryness, redissolved in a mobile phase of methanol/water
(55/45) and separated on a 4p Novapak C18 column. The
absorption of the eluate was measured at 229 nm. The intra-
and inter-assay cofficients of variations were 2.5 and 5%
respectively. In some samples a peak of unknown material
interfered with the etoposide peak; they were resolved by
increasing the mobile phase to a 50/50 ratio. For each course
the area under the etoposide curve (AUC) was calculated as
follows: mean etoposide concentration x 120 h x 3,600 s. We
assumed that the over-estimate made between time 0 and
17 h was approximately equal to the underestimate when the
AUC after 120 h was excluded.
The correlation r coefficients were measured. The means of
the values between responders and non-responders were com-
pared using the non-paired two-sided Student's t test. Group
variances were not different according to the F test. When
several kinetic measurements were available, their average
value was used. For myelosuppression comparison, the X2
test was used; the number of groups was reduced to three:
group 1 for toxic grade 0, group 2 for grades 1 and 2, and
group 3 for grades 3 and 4.
As early as the first blood sample, on average 17 h after
starting the infusion, the plasma concentration of etoposide
reached a plateau in non-responders. In responders the
plasma concentration continued to rise for 96 h but was only
significantly different from that of the non-responders on
third, fourth and fifth days (Figure 1). The plateau was
reached quickly, although etoposide terminal half-life is ap-
proximately 8 h (Clark & Slevin, 1987). The etoposide con-
centration was not constant throughout the duration of the
infusion; the mean coefficent of variation was 15% (6-33%).
There was considerable variation between patients. As a
consequence, patient doses were not significantly correlated
to plasma etoposide concentration (r = 0.325, n.s.) for all the
kinetic studies, even when the dose was expressed per square
metre.
Both etoposide plasma concentration and etoposide AUC
were clearly correlated with serum creatinine concentration
(r = 0.579, P<0.001 and r= 0.472, P<0.01 respectively)
which is probably the result of 50% of the etoposide being
cleared by the kidney (Clark & Slevin, 1987).
Toxicity was significantly higher in responders as com-
pared to non-responders, but it was unrelated to the pharma-
cokinetics, whereas efficacy was related to several variables.
In responders etoposide concentration was higher as early as
the first assay, but it was significantly related with efficacy
only from day 3 (see Table I and Figure 1). Etoposide mean
concentration, AUC and clearance were also significantly
higher in responders, as well as the creatinine concentration
and clearance (Table I).
These results establish, for the first time as far as we
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Figure 1 Etoposide concentration (± standard deviation) in sera
of seven patients who responded (continuous line) and seven
patients who did not respond (dotted line) during continuous
infusion. Concentration were significantly different (t test) on
days 3, 4 and 5.
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plasma concentration and AUC; a similar relationship was
established for teniposide by Rodman et al. (1987). Our data
suggest that renal impairment enhances etoposide concentra-
tion, as also reported by D'Incalci et al. (1986), and thus
increases the chance of a response. This hypothesis was
confirmed by the correlations observed between creatinine
concentration (and clearance) and etoposide concentration,
and efficacy. In this study CDDP did not cause impaired
renal function.
CDDP and CPM were probable contributors to chemo-
therapy efficacy but cannot be estimated. For this reason we
conclude that when etoposide concentration and AUC were
low the treatment was not efficient: six out of seven non-
responders compared to two out of seven responders had
plasma concentrations<2.5ymol 1'. These results led us to
initiate a phase I/II study for an adaptative control of
etoposide administration, with a dose adjustment at 28 h as
proposed by Ratain et al. (1989).
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Table I Patients' characteristics
Clear. Clear.
Prior Dose Course Css AUC etopos. creat. Creatinine Tox.
Patient Diagnosis chem. Co-chem. VPJ6day-' no. (p.mol1') (mol1'I s) (mls' m-2) (jmol1') PMN
1-NR NSCLC no CDDP 90 1 1.36 0.59 0.721 0.994 64 0
CDDP 90 3 2.25 0.97 0.437 1.100 64 0
2-NR CUP no CDDP 90 1 2.03 0.88 0.485 0.761 88 0
CDDP 90 2 1.92 0.83 0.514 0.911 98 0
3-NR NSCLC no CDDP 50 2 1.16 0.50 0.611 64 4
4-NR NSCLC no CDDP 90 1 2.73 1.18 0.349 1.328 63 1
CDDP 90 2 2.11 0.94 0.452 80 0
CDDP 90 3 3.44 1.46 0.291 0.628 93 1
5-NR NSCLC no CDDP 100 1 1.88 0.81 0.599 80 1
CDDP 100 2 2.29 0.99 0.491 83 0
CDDP 100 3 2.74 1.18 0.410 99 0
6-NR CUP no CDDP 100 1 1.84 0.80 0.594 74 3
CDDP 100 2 2.64 1.14 0.415 103 2
7-NR NSCLC no CDDP 70 1 1.72 0.74 0.578 60 3
CDDP 70 2 1.94 0.84 0.512 63 3
CDDP 70 3 2.31 1.00 0.435 69 3
8-PR BREAST yes CDDP 90 1 2.54 1.10 0.370 91 4
CDDP 90 2 2.80 1.21 0.337 77 4
9-PR NHL no CPM 100 2 3.10 1.34 0.352 108 4
CPM 100 3 3.33 1.44 0.329 0.522 87 4
10-PR NSCLC yes CDDP 60 3 2.63 1.14 0.249 84 2
11-PR NSCLC no CDDP 120 4 2.82 1.22 0.384 103 2
CDDP 120 5 3.82 1.65 0.284 98 2
CDDP 120 6 3.85 1.66 0.281 119 2
12-PR NSCLC no CDDP 80 1 3.03 1.35 0.323 0.654 101 4
CDDP 90 2 3.84 1.69 0.266 0.700 101 1
CDDP 90 3 2.78 1.30 0.346 0.735 97 1
13-PR NSCLC no CDDP 100 1 1.74 0.75 0.645 82 3
CDDP 100 2 2.04 0.88 0.551 79 3
14-PR NSCLC no CDDP 100 1 2.17 0.94 0.510 77 n.d.
CDDP 100 2 2.14 0.92 0.517 77 n.d.
CDDP 100 3 2.40 1.07 0.397 79 n.d.
Student's t valuea 1.11 2.76 2.71 2.66 4.31 2.2 7.5
P n.s. <0.02 <0.02 <0.05 <0.001 <0.05 <0.05
Partial responder (PR) and non-responder (NR), before and concomitant with chemotherapy, number of the course, plasma concentration of
etoposideatsteadystate, areaunderthecurve,plasmaclearanceofetoposideandofcreatininepersquaremetre, plasmaconcentrationofcreatinineat
the beginning ofthecourse, toxicity evaluation bypolymorphonuclear cell count. NSCLC: non-small cell lung cancer. CUP: carcinome ofunknown
primary. NHL: non-Hodgkin's lymphoma. n.d.: not determined. aWhen several kinetics were available, their average values were used. See text for
more information. For myelosuppression comparison, the X2 test was used.
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